Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

B. Douglas Smith, Mark Levis, Miloslav Beran, Francis Giles, Hagop Kantarjian, Karin Berg, Kathleen M. Murphy, Tianna Dauses, Jeffrey Allebach, Donald Small

Research output: Contribution to journal › Article › peer-review

507 Scopus citations

Fingerprint

Dive into the research topics of 'Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds